Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer

Front Cell Dev Biol. 2023 Mar 16:11:1179559. doi: 10.3389/fcell.2023.1179559. eCollection 2023.

Xu Zhou^{1

2}, Kai Hu^{1

2}, Peter Bailey^{1

2

3}, Christoph Springfeld⁴, Susanne Roth¹, Roma Kurilov⁵, Benedikt Brors^{4

5}, Thomas Gress⁶, Malte Buchholz⁶, Jingyu An^{1

2}, Kongyuan Wei^{1

2}, Teresa Peccerella^{1

2}, Markus W Büchler¹, Thilo Hackert¹, John P Neoptolemos^{1

2}

¹ Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
² Section of Surgical Research, Heidelberg University Hospital, Heidelberg, Germany.
³ Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
⁴ Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
⁵ Division of Applied Bioinformatics, German Cancer Research Center, Heidelberg, Germany.
⁶ Department of Gastroenterology and Endocrinology, Philipps University of Marburg, Marburg, Germany.

Abstract

[This corrects the article DOI: 10.3389/fcell.2021.743908.].

Keywords: ESPAC; clinical trials; molecular subtypes; next generation sequencing; precision medicine; structural variants; transcriptomes.